A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial (Q33675468)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Désirée van der Heijde

11

object named as

Désirée van der Heijde

0 references

George A. Howard

object named as

George Howard

10

0 references

Jeffrey R Curtis

4

object named as

Jeffrey R Curtis

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

E. William St. Clair

6

object named as

E William St Clair

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Larry W Moreland

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

James R O'Dell

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Harold E Paulus

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Joan M Bathon

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

S Louis Bridges

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jie Zhang

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Theresa McVie

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Stacey S Cofield

12

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

TEAR Investigators

13

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2824-2835

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Are biologics more effective than classical disease-modifying antirheumatic drugs?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

How to read radiographs according to the Sharp/van der Heijde method.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Random-effects models for longitudinal data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4036119

21 June 2018

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FART.34498

21 January 2018

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/22508468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.34498

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33675468&oldid=1619724806"